These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
590 related articles for article (PubMed ID: 27021209)
21. Pharmacophore-based virtual screening, biological evaluation and binding mode analysis of a novel protease-activated receptor 2 antagonist. Cho NC; Seo SH; Kim D; Shin JS; Ju J; Seong J; Seo SH; Lee I; Lee KT; Kim YK; No KT; Pae AN J Comput Aided Mol Des; 2016 Aug; 30(8):625-37. PubMed ID: 27600555 [TBL] [Abstract][Full Text] [Related]
22. Constructing an atomic-resolution model of human P2X7 receptor followed by pharmacophore modeling to identify potential inhibitors. Ahmadi M; Nowroozi A; Shahlaei M J Mol Graph Model; 2015 Sep; 61():243-61. PubMed ID: 26298810 [TBL] [Abstract][Full Text] [Related]
24. Identification and characterization of the chicken galanin receptor GalR2 and a novel GalR2-like receptor (GalR2-L). Ho JC; Jacobs T; Wang Y; Leung FC Gen Comp Endocrinol; 2012 Nov; 179(2):305-12. PubMed ID: 22982974 [TBL] [Abstract][Full Text] [Related]
25. Structure of the human galanin receptor 2 bound to galanin and Gq reveals the basis of ligand specificity and how binding affects the G-protein interface. Heo Y; Ishimoto N; Jeon YE; Yun JH; Ohki M; Anraku Y; Sasaki M; Kita S; Fukuhara H; Ikuta T; Kawakami K; Inoue A; Maenaka K; Tame JRH; Lee W; Park SY PLoS Biol; 2022 Aug; 20(8):e3001714. PubMed ID: 35913979 [TBL] [Abstract][Full Text] [Related]
26. In silico mapping of allosteric ligand binding sites in type-1 cannabinoid receptor. Sabatucci A; Tortolani D; Dainese E; Maccarrone M Biotechnol Appl Biochem; 2018 Jan; 65(1):21-28. PubMed ID: 28833445 [TBL] [Abstract][Full Text] [Related]
27. Ligand binding properties of human galanin receptors. Jurkowski W; Yazdi S; Elofsson A Mol Membr Biol; 2013 Mar; 30(2):206-16. PubMed ID: 23237663 [TBL] [Abstract][Full Text] [Related]
28. Molecular characterization of the ligand binding site of the human galanin receptor type 2, identifying subtype selective interactions. Lundström L; Sollenberg UE; Bartfai T; Langel U J Neurochem; 2007 Dec; 103(5):1774-84. PubMed ID: 17953676 [TBL] [Abstract][Full Text] [Related]
29. Virtual Screening and Molecular Dynamics Study of Potential Negative Allosteric Modulators of mGluR1 from Chinese Herbs. Jiang L; Zhang X; Chen X; He Y; Qiao L; Zhang Y; Li G; Xiang Y Molecules; 2015 Jul; 20(7):12769-86. PubMed ID: 26184151 [TBL] [Abstract][Full Text] [Related]
30. Insights into the interaction of negative allosteric modulators with the metabotropic glutamate receptor 5: discovery and computational modeling of a new series of ligands with nanomolar affinity. Anighoro A; Graziani D; Bettinelli I; Cilia A; De Toma C; Longhi M; Mangiarotti F; Menegon S; Pirona L; Poggesi E; Riva C; Rastelli G Bioorg Med Chem; 2015 Jul; 23(13):3040-58. PubMed ID: 26014480 [TBL] [Abstract][Full Text] [Related]
31. Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions. Lu S; Zhang J J Med Chem; 2019 Jan; 62(1):24-45. PubMed ID: 29457894 [TBL] [Abstract][Full Text] [Related]
32. Probe dependence and biased potentiation of metabotropic glutamate receptor 5 is mediated by differential ligand interactions in the common allosteric binding site. Hellyer SD; Sengmany K; Keller AN; Christopoulos A; Leach K; Gregory KJ Biochem Pharmacol; 2020 Jul; 177():114013. PubMed ID: 32389635 [TBL] [Abstract][Full Text] [Related]
33. Accelerated structure-based design of chemically diverse allosteric modulators of a muscarinic G protein-coupled receptor. Miao Y; Goldfeld DA; Moo EV; Sexton PM; Christopoulos A; McCammon JA; Valant C Proc Natl Acad Sci U S A; 2016 Sep; 113(38):E5675-84. PubMed ID: 27601651 [TBL] [Abstract][Full Text] [Related]
34. A novel GalR2-specific peptide agonist. Runesson J; Saar I; Lundström L; Järv J; Langel U Neuropeptides; 2009 Jun; 43(3):187-92. PubMed ID: 19467704 [TBL] [Abstract][Full Text] [Related]
35. Insights into the binding modes of CC chemokine receptor 4 (CCR4) inhibitors: a combined approach involving homology modelling, docking, and molecular dynamics simulation studies. Gadhe CG; Kim MH Mol Biosyst; 2015 Feb; 11(2):618-34. PubMed ID: 25474265 [TBL] [Abstract][Full Text] [Related]
36. Activation and Allosteric Modulation of Human μ Opioid Receptor in Molecular Dynamics. Bartuzi D; Kaczor AA; Matosiuk D J Chem Inf Model; 2015 Nov; 55(11):2421-34. PubMed ID: 26517559 [TBL] [Abstract][Full Text] [Related]
37. Effect of hydrophobic and hydrogen bonding interactions on the potency of ß-alanine analogs of G-protein coupled glucagon receptor inhibitors. Venugopal PP; Das BK; Soorya E; Chakraborty D Proteins; 2020 Feb; 88(2):327-344. PubMed ID: 31443129 [TBL] [Abstract][Full Text] [Related]
38. Opportunities and Challenges in the Discovery of Allosteric Modulators of GPCRs. Bartuzi D; Kaczor AA; Matosiuk D Methods Mol Biol; 2018; 1705():297-319. PubMed ID: 29188568 [TBL] [Abstract][Full Text] [Related]
39. Theoretical study of the binding profile of an allosteric modulator NS-1738 with a chimera structure of the α7 nicotinic acetylcholine receptor. Kuang G; Wang X; Halldin C; Nordberg A; Långström B; Ågren H; Tu Y Phys Chem Chem Phys; 2016 Oct; 18(40):28003-28009. PubMed ID: 27711412 [TBL] [Abstract][Full Text] [Related]
40. Mouse Spexin: (I) NMR Solution Structure, Docking Models for Receptor Binding, and Histological Expression at Tissue Level. Wong MKH; He M; Sze KH; Huang T; Ko WKW; Bian ZX; Wong AOL Front Endocrinol (Lausanne); 2021; 12():681646. PubMed ID: 34276561 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]